0000899243-21-040831.txt : 20211020 0000899243-21-040831.hdr.sgml : 20211020 20211020184452 ACCESSION NUMBER: 0000899243-21-040831 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211020 FILED AS OF DATE: 20211020 DATE AS OF CHANGE: 20211020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nuss John CENTRAL INDEX KEY: 0001874108 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40928 FILM NUMBER: 211335177 MAIL ADDRESS: STREET 1: C/O VENTYX BIOSCIENCES, INC. STREET 2: 332 ENCINITAS BLVD. SUITE 200 CITY: ENCINITAS STATE: CA ZIP: 92024 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ventyx Biosciences, Inc. CENTRAL INDEX KEY: 0001851194 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832996852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: (858) 945-2393 MAIL ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-10-20 0 0001851194 Ventyx Biosciences, Inc. VTYX 0001874108 Nuss John C/O VENTYX BIOSCIENCES, INC. 662 ENCINITAS BLVD, SUITE 250 ENCINITAS CA 92024 0 1 0 0 Chief Scientific Officer Common Stock 308696 D Stock Option (right to buy) 0.20 2029-03-27 Common Stock 193557 D Stock Option (right to buy) 0.20 2030-05-01 Common Stock 96778 D Stock Option (right to buy) 3.54 2021-02-26 2031-02-26 Common Stock 7972 D Stock Option (right to buy) 8.04 2031-09-18 Common Stock 193404 D Includes 10,754 shares subject to repurchase. Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 6, 2019. Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 1, 2020. Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the options shall vest on the one year anniversary of the Vesting Commencement date, and, thereafter, one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean September 17, 2021. Exhibit 24 - Power of Attorney /s/ Christopher Krueger, as Attorney-in-Fact 2021-10-20 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                  POWER OF ATTORNEY

      The undersigned, as a Section 16 reporting person of Ventyx Biosciences,
Inc. (the "Company"), hereby constitutes and appoints Raju Mohan, Christopher
Krueger, Martin D. Auster, Martin Waters, Raymond Multer, and Brandon Shaw the
undersigned's true and lawful attorneys-in-fact to:

      1.  complete and execute Forms 3, 4 and 5 and other forms and all
          amendments thereto as such attorneys-in-fact shall in their discretion
          determine to be required or advisable pursuant to Section 16 of the
          Securities Exchange Act of 1934 (as amended) and the rules and
          regulations promulgated thereunder, or any successor laws and
          regulations, as a consequence of the undersigned's ownership,
          acquisition or disposition of securities of the Company; and

      2.  do all acts necessary in order to file such forms with the Securities
          and Exchange Commission, any securities exchange or national
          association, the Company and such other person or agency as the
          attorneys-in-fact shall deem appropriate.

      The undersigned hereby ratifies and confirms all that said attorneys-in-
fact and agent shall do or cause to be done by virtue hereof.  The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with Section 16 of
the Securities Exchange Act of 1934 (as amended).

      This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 20th day of October, 2021.


                                    Signature:  /s/ John Nuss
					      ------------------------------
                                    Print Name:   John Nuss
					       -----------------------------